Millennium Management
QNCX icon

Millennium Management’s Quince Therapeutics QNCX Stock Holding History

Millennium Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
70,779
+58,260
+465% +$1.34M ﹤0.01% 4151
2026
Q1 		$254K Buy
12,519
+6,567
+110% +$1.32M ﹤0.01% 5074
2025
Q4 		$3.99M Sell
5,952
-982
-14% -$494K ﹤0.01% 3268
2025
Q3 		$2.26M Buy
6,934
+6,381
+1,154% +$2.12M ﹤0.01% 3942
2025
Q2 		$183K Buy
+553
New +$126K ﹤0.01% 5392
2024
Q3 		– Sell
-183
Closed -$27.4K – 6400
2024
Q2 		$27.4K Sell
183
-85
-32% -$15.4K ﹤0.01% 5497
2024
Q1 		$56.9K Sell
268
-29
-10% -$7.21K ﹤0.01% 5668
2023
Q4 		$62.4K Sell
297
-3
-1% -$601 ﹤0.01% 5435
2023
Q3 		$67.1K Sell
300
-7
-2% -$1.83K ﹤0.01% 5428
2023
Q2 		$92.4K Sell
307
-933
-75% -$290K ﹤0.01% 5345
2023
Q1 		$387K Sell
1,240
-1,739
-58% -$340K ﹤0.01% 4747
2022
Q4 		$380K Buy
2,979
+689
+30% +$115K ﹤0.01% 4934
2022
Q3 		$609K Buy
2,290
+563
+33% +$214K ﹤0.01% 4784
2022
Q2 		$767K Buy
1,727
+1,396
+422% +$987K ﹤0.01% 4611
2022
Q1 		$410K Sell
331
-2,502
-88% -$3.4M ﹤0.01% 5271
2021
Q4 		$7.15M Buy
2,833
+2,810
+12,217% +$17.1M ﹤0.01% 2528
2021
Q3 		$419K Buy
+23
New +$366K ﹤0.01% 5508
2021
Q2 		– Sell
-33
Closed -$239K – 6995
2021
Q1 		$239K Sell
33
-487
-94% -$3.5M ﹤0.01% 5388
2020
Q4 		$2.89M Buy
+520
New +$4.61M ﹤0.01% 2928
2020
Q3 		– Sell
-126
Closed -$1.17M – 4749
2020
Q2 		$1.17M Sell
126
-2
-2% -$18.3K ﹤0.01% 2906
2020
Q1 		$1.17M Buy
+128
New +$1.26M ﹤0.01% 2367
2019
Q4 		– Sell
-106
Closed -$529K – 4555
2019
Q3 		$529K Buy
106
+44
+71% +$271K ﹤0.01% 3222
2019
Q2 		$531K Buy
+62
New +$370K ﹤0.01% 3186

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management's QNCX Position: Q2 2026 in Review

Millennium Management increased its Quince Therapeutics (QNCX) stake by 465% in Q2 2026, buying an estimated $1.34M and bringing the position to 70,779 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4151.

Millennium Management first reported a position in QNCX in Q2 2019 and has held it in 23 quarters since. The position peaked at $7.15M in Q4 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Millennium Management held 70,779 shares of Quince Therapeutics worth $1.29M as of Q2 2026.
  • Millennium Management bought 58,260 Quince Therapeutics shares in Q2 2026, an estimated $1.34M.
  • Quince Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #4151 holding.
  • Millennium Management first reported a position in Quince Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • Millennium Management's Quince Therapeutics position peaked at $7.15M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.